The Cigna Group vs CLOVER HEALTH INVESTMENTS, CORP. /DE, two Managed Care stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where CI and CLOV diverge most: on net margin, CI reads 2.2% and CLOV reads -2.6%; on return on equity, CI reads 14.5% and CLOV reads -16.8%. The rest of the comparable metrics sit closer together. What CI's price implies is a bet that sits within the historical range. What CLOV's price implies is an extreme bet versus history and the cohort (earnings-power basis). The bull and bear cases for each are in their full reports below.
| Metric | CI | CLOV |
|---|---|---|
| Price | $279.03 | $4.16 |
| Market cap | $73.7B | $2.2B |
| Sector | Managed Care | Managed Care |
| Stage | Mature | Growth |
| P/E | 11.5 | — |
| P/B | 1.72 | 6.53 |
| P/S | 0.26 | 1.00 |
| EV/EBITDA | 5.5 | — |
| Revenue growth | +7.8% | +47.7% |
| Operating margin | 3.7% | 3.6% |
| Net margin | 2.2% | -2.6% |
| Return on equity | 14.5% | -16.8% |
| Return on assets | 4.0% | -8.2% |
| Return on invested capital | 18.1% | -13.3% |
| FCF yield | 13.9% | 2.5% |
| Dividend yield | 2.2% | — |
| Debt / equity | 0.07 | 0.00 |
| Current ratio | 0.85 | 1.33 |
| Altman Z (solvency) | 2.62 | 2.66 |
| Piotroski F (quality) | 6 / 9 | 8 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.